Healthcare and pharma funding sees 1440% surge in december 2024
Early-stage investments dominate as sector funding reaches $69.8 million, led by deals from 3Gen Consulting, Laurus Bio, and Orange Health
According to a Tracxn report covering 1 December 2024 to 31 December 2024, funding in the healthcare and pharma sector reached $69.8 million in December 2024. This represents a 1440.84 per cent increase from $4.53 million in November 2024. However, it reflects a 6.93 per cent decline compared to $75 million recorded in December 2023.
The majority of funding in December came from early-stage rounds, accounting for 78.9 per cent of the total investments. Late-stage funding contributed 13.9 per cent, while seed-stage funding comprised 7.3 per cent of the overall funding during the month.
Notable funding rounds in December 2024 included 3Gen Consulting, Laurus Bio, and Orange Health, which raised $22 million, $18.9 million, and $12 million, respectively. Active investors during the period included ASVF, CK Jaipuria Family Office, and Aeravti Ventures.
The surge in funding highlights growing interest in the healthcare and pharma sector, particularly in early-stage ventures, as investors continue to back innovation and expansion in the industry.
- Advertisement -